Onkologie. 2014:8(3):124-128

Systemic therapy in the bone sarcoma treatment

Dagmar Adámková Krákorová, Štěpán Tuček
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

Bone sarcomas are extremely rare neoplasms. Early diagnosis and effective treatment are significant for the therapy achievment. According

to the high specialization, multidisciplinary treatments planning by an experienced team is mandatory in all cases of bone sarcoma.

Keywords: bone sarcomas, multidisciplinary treatment, chemotherapy, target therapy

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Adámková Krákorová D, Tuček Š. Systemic therapy in the bone sarcoma treatment. Onkologie. 2014;8(3):124-128.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Stiller CA, Craft AW, Corazziari I. Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study. Eur J Cancer 2001; 37: 760-766. Go to original source... Go to PubMed...
    2. Isakoff MF, Harris MJ, Beghart MC, Grier HE. Bone Sarcomas in: Cancer in Adolescents and Young Adults, editors Bleyer WA, Barr RD. Springer-Verlag Berlin Heidelberg New York 2007, ISSN 1613-5318. Chapter 12, 203-218. Go to original source...
    3. Bleyer WA, O´Leary M, Barr R, Ries (eds). Cancer epidemiology in Older Adolescents and Young Adults 15 to 29 years of Age, including SEER Incidence and Survival, 1975-2000. National Cancer Institute, 2006, NIH Pub. No 06-5767, Bethesda MD, www.seer.cancer.gov/publications.
    4. Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. Health Organization classification of tumours of soft tissue and bone, 4th ed. Lyon: IARC Press, 2013.
    5. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res 2002: 40-52. Go to original source... Go to PubMed...
    6. Bovee JVMG, Cleton-Jansen AM, Taminiau AHM, et al. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005; 6: 599-607. Go to original source... Go to PubMed...
    7. Cancer Management: A Multidisciplinary Approach, 12th edition, edited by Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, 2009, Chapter 21, 569-583.
    8. Judson J. Role of expert centres in the management of sarcomas. Eur J Cancer, Suppl. II, 2013: 310-311. Go to original source... Go to PubMed...
    9. Bone sarcomas: ESMO Clinical Practise Guidlines for diagnosis, treatment and follow up, Annals of Oncology 2012, Oct Vo 23/Suplement 7/, vii 100-109. Go to original source... Go to PubMed...
    10. Bramer JA, van Linge JH, Grimer RJ, et al. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol 2009; 35: 1030-1036. Go to original source... Go to PubMed...
    11. Adámkova Krákorová D. Prognostické faktory konvenčního osteosarkomu dospělých pacientů. Klin Onkol 2012; 25(5): 346-358. Go to PubMed...
    12. Bielack SS, Bielack KB, Delling G, et al. Prognostic factors in high grade osteosarcoma of the extremities or trunk: An analysis of 1702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20: 776-790. Go to original source... Go to PubMed...
    13. Bacci G, Longhi A, Versaci M, et al. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15 year experience in 789 patients treated at a single institution. Cancer 2006; 106(5): 1154-1161. Go to original source... Go to PubMed...
    14. NCCN Clinical Practise Guidlines in Oncology, Bone cancer, V. 1/2014, www.nccn.org.
    15. Bacci G, Lonhgi A, Beroni F, et al. Primary high grade osteosarcoma: comparsion between preadolescent and older patients. Journal of Pediatr Hematol Oncology, 2005; 27: 129-134. Go to original source... Go to PubMed...
    16. Goorim AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric oncology group study POG-8651. J Clin Oncol 2003; 8: 1574-1580. Go to original source... Go to PubMed...
    17. Bielack SS, Machatschek JN, Flege S, et al. Delaying surgery with chemotherapy for osteosarcoma of the extremities. Expert Opin Pharmacother 2004; 5: 1243-1256. Go to original source... Go to PubMed...
    18. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. J Clin Oncol 2008; 26: 633-638. Go to original source... Go to PubMed...
    19. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009; 115(7): 1531-1543. Go to original source... Go to PubMed...
    20. Grignari G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012; 23(2): 508-516. Go to original source... Go to PubMed...
    21. Gill J, et al. New targets and approaches in osteosarcoma. Pharmacology & Therapeutics 2013 Jan; 137 (1): 89-99. Go to original source... Go to PubMed...
    22. Gelderblom H, Hogendoorn PCW, Dijkstra SD et al. The clinical approach towards chondrosarcoma. Oncologist 2008; 13: 320-329. Go to original source... Go to PubMed...
    23. Riedel RF, Larrier N, Dodd L, et al. The clinical management of chondrosarcoma. Curr Treat Options Oncol 2009; 10: 94-106. Go to original source... Go to PubMed...
    24. Dickey ID, Rose PS, Fuchs B, et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. J Bone Joint Surg Am 2004; 86-A: 2412-2418. Go to original source...
    25. Grimer RJ, Gosheger G, Taminiau A, et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer 2007; 43: 2060-2065. Go to original source... Go to PubMed...
    26. Cesari M, Bertoni F, Bacchini P, et al. Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori 2007; 93: 423-427. Go to original source... Go to PubMed...
    27. Dantonello TM, Int-Veen C, Leuschner I, et al. Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer 2008; 112: 2424-2431. Go to original source... Go to PubMed...
    28. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing´s tumor of bone: analysis of 975 patient from European Intergroup Cooperative Ewing´s Sarcoma Study Group. J Clin Oncol 2000; 18: 3108-3114. Go to original source... Go to PubMed...
    29. Bacci G, Longhi A, Ferrari S, et al. Prognostic factors in non-metastatic Ewing´s Sarcoma tumor of bone: an analysis of 579 patients treatet at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006; 45: 469-475. Go to original source... Go to PubMed...
    30. Lee J, Hoang BH, Ziogas A, et al. Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer 2010; 116: 1964-1973. Go to original source... Go to PubMed...
    31. Pieper S, Ranft A, Braun-Munzinger G, et al. Ewing´s tumor ower the age of 40: a retrospective analysis of 47 patients treated according to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G.99. Onkologie, 2008. Dec, 657-663. Go to original source...
    32. Paulussen M, Ahrens S, Juergens HF. Cure rates in Ewing tumor patient aged over 15 years are better in pediatric oncology units. Results of GPOH CESS/EICESS studies. Proc Am Soc Clin Oncol 2003; 22: 816.
    33. EWING 2008 treatment manual, version 1-010607, ewing@uni-muenster.de.
    34. Naomi J Balamuth, Richard B Wormer. Ewing´s sarcoma. Lancet Oncol 2010; 11: 184-192. Go to original source... Go to PubMed...
    35. Engelhardt M, Zeiser R, Ihorst G, et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in adult patiens with high-risk or advanced Ewing and soft tissue sarcoma. J Cancer Res Clin Oncol. 2007; 133(1): 1-11. Go to original source... Go to PubMed...
    36. Ferrari S, Sundby Hal K, Luksch R, et al. Non metastatic Ewing family tumors: High-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Annals of Oncology 2011; 22: 1221-1227. Go to original source... Go to PubMed...
    37. Gaspar N, Rey A, Berard PM, et al. Risk adapted chemotherapy for localised Ewing´s sarcoma of bone: The French EW93 study. Eur J Cancer 2012; 48: 1376-1385. Go to original source... Go to PubMed...
    38. Anderson P, Kopp L, Anderson N, et al. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcoma (Ewing´s sarcoma and osteosarcoma), Expert Opin. Investig. Drugs 2008; 17(11): 1703-1715. Go to original source... Go to PubMed...
    39. Hunold A, Weddeling N, Paulussen M, et al.Topotecan and cyclofosfamid in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006; 47: 795-800. Go to original source... Go to PubMed...
    40. Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomid for Ewing sarcoma. The Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009; 53: 1029-1034. Go to original source... Go to PubMed...
    41. Wagner LM, MCAlliser N, Goldsby RE, et al. Temozolomid and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer. 2007; 48: 132-139. Go to original source... Go to PubMed...
    42. Navid F, Willet JR, Mc Carville MB, et al. Combination of gemcitabin and docetaxel in the treatment of childrens and young adults with refractoy bone sarcoma. Cancer 2008; 113: 419-425. Go to original source... Go to PubMed...
    43. Mora J, Cruz CO, Parareda A, et al. Treatment of relapsed/ refractory pediatric sarcomas with gemcitabine and docetaxel. J Pediatr Hematol Onco 2009; 31(10): 723-729. Go to original source... Go to PubMed...
    44. Stacchiotti S, Longhi A, Ferraresi V, et. al. Phase II study of imatinib in advanced chordoma. J. Clin Oncol 2012; 30: 914-920. Go to original source... Go to PubMed...
    45. Casali PG, Stacchioti S, Grosso F, et al. Adding cisplatin (CDDP) to imatinib (IM) re-establishes tumor response following secondary resistance to imatinib in advanced chordoma. J. Clin Oncol 2007; 25: A 10038. Go to original source...
    46. Thomas DM, Henshaw R, Skubitz R. Denosumab in patients with giant-cell tumor of bone, an open-lable, phase II study. Lancet Oncol 2010; 11: 275-280. Go to original source... Go to PubMed...
    47. Chawla S, Henshaw R, Seeger L. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013; 14(9): 901-908. Go to original source... Go to PubMed...
    48. Biermann JS. Updates in the treatment of bone cancer. J Natl Compr Canc Netw. 2013; 11(5 Suppl): 681-683. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.